Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
Launched by YALE UNIVERSITY · Jun 14, 2023
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial, called "Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda," is designed to see how well a new program helps people with tuberculosis (TB), especially those also living with HIV. The program will use trained peers—people who have experienced TB or HIV themselves—to provide education and support to others. Researchers want to find out if this approach improves treatment outcomes and helps participants follow their treatment plans better.
To be eligible for this study, participants must be adults or older adolescents (18 years and older) who are newly diagnosed with TB and registered in the National TB Program. If someone is living with HIV and receiving treatment, they can also join. However, people who have certain types of severe TB or those who live too far from the clinic will not be able to participate. While this study is not yet recruiting participants, those who join can expect to receive valuable support and guidance from peers who understand what they are going through. This trial aims to make a positive difference in how people manage their TB and HIV treatment.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- TB outcomes:
- • Sites will enroll consecutive adults and older adolescents (age ≥18) recorded as new TB cases in the on-site National TB Program TB treatment register.
- ART outcomes:
- • Participants must be documented as a People Living with HIV (PLH) in the TB register.
- Exclusion Criteria:
- • TB outcomes: Individuals who are
- • transferring in from off-site
- • diagnosed with possible or confirmed drug-resistant TB
- • residing \>40 km from the clinic
- • lacking mental capacity to participate in peer counseling
- • will be excluded from this study.
- ART outcomes:
- • The investigators will exclude those with TB meningitis or TB pericarditis for which immediate ART is contraindicated; and those with central nervous system TB or TB osteomyelitis because these forms of TB have a different treatment duration.
About Yale University
Yale University, a prestigious Ivy League institution located in New Haven, Connecticut, is renowned for its commitment to advancing medical research and clinical innovation. With a rich history of academic excellence and a robust infrastructure for scientific inquiry, Yale serves as a leading sponsor for clinical trials aimed at improving patient care and developing new therapeutic approaches. The university's multidisciplinary teams of researchers and clinicians collaborate to conduct rigorous and ethical studies, leveraging cutting-edge technologies and methodologies to address critical health challenges. Through its dedication to fostering an environment of inquiry and discovery, Yale University plays a pivotal role in translating research findings into clinical practice, ultimately enhancing health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kampala, , Uganda
Patients applied
Trial Officials
J. Lucian Davis, MD
Principal Investigator
Yale University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported